

May 12, 2009



## ASCO Snapshot: Prostate Cancer

Event: American Society of Clinical Oncology, May 29—June 2,



### Market Leaders

**Sanofi Aventis** (NYSE:SNY): Taxotere 2008 Sales USD 2697m

[Sanofi Aventis' Taxotere patent lawsuit leaves attorneys perplexed on noncompliance with 'offer of confidential access' contention - analysis \(Pharmawire\)](#)

**Takeda** (TYO:4502): Lupron Depot 2008 Sales USD 1291m

**AstraZeneca** (NYSE:AZN): Casodex 2008 Sales USD 1258m, Zoladex 2008 Sales USD 1138m

[AstraZeneca denied interlocutory injunctions on generic Casodex and Seroquel; reimbursement and IP rights should be more aligned \(Pharmawire\)](#)

**GlaxoSmithKline** (NYSE:GSK): Avodart 2008 Sales USD 582m

[GlaxoSmithKline's Avodart found to reduce prostate cancer risk in trial](#)

**Ipsen** (EPA:IPN): Trelstar 2008 Sales USD 326m

**Merck** (NYSE:MRK): Proscar 2008 Sales USD 323m



### Unpartnered Targets in Development

**GTX Pharmaceuticals** (NASDAQ:GTXI): acapodene: market cap USD 353m

[GTX plans to market two versions of toremifene in the US on its own, CEO says \(Pharmawire\)](#)

[GTX's 20mg toremifene might not provide significant enough benefit to merit approval, physicians suggest \(Pharmawire\)](#)

**Dendreon** (NASDAQ:DNDN): sipuleucel-T: market cap USD 2120m

[Dendreon's Provenge may show greater benefit in patients with earlier stage prostate cancer, sources say \(Pharmawire\)](#)

[Dendreon Provenge's complicated manufacturing could stain positive efficacy data, sources say \(Pharmawire\)](#)

[Dendreon's initial Provenge Phase III trials unlikely to contribute much to FDA submission package, biostatisticians say \(Pharmawire\)](#)

**Cougar Biotechnology** (NASDAQ:CGRB): abiraterone acetate: market cap USD 727m

[Takeda actively prospecting late-stage cancer and diabetes drug targets, source says \(Pharmawire\)](#)

[Cougar Biotech's CB7630 shows response in shrinking tumors, but physicians say excitement is tempered until more data arrives \(Pharmawire\)](#)

[GTX's 80mg toremifene may have risks that outweigh benefits, physicians say; CEO argues drug has safety profile that merits approval \(Pharmawire\)](#)

**Medivation** (NASDAQ:MDVN): MDV3100: market cap USD 602m

[Medivation's MDV3100 will need to show improvement in overall survival for approval in prostate cancer, which may be difficult, physicians say \(Pharmawire\)](#)

[Medivation's prostate cancer treatment MDV3100 needs large-scale studies to determine if seizure risk is a concern, physicians say \(Pharmawire\)](#)

**Marshall Edwards** (NASDAQ:MSHL)/**Novogen** (NASDAQ:NVGN): phenoxodiol: market cap 39m each

[Novogen concentrates resources on oncology portfolio, puts other programs on hold](#)

**Active Biotech AB** (STO:ACTI): tasquinimod: cash USD 7m, cash burn 4 months

[Active Biotech in early talks to partner both lupus candidate paquinimod and TasQ for prostate cancer, executives say \(Pharmawire\)](#)

**Poniard Pharmaceuticals** (NASDAQ:PARD): picoplatin: cash 33m, cash burn 12 months

[Poniard discussing the potential for picoplatin partnership, its cytotoxic platinum based chemotherapy, CEO says \(Pharmawire\)](#)

[Poniard Pharmaceutical's picoplatin likely to experience difficulty improving disease outcomes in hormone refractory prostate cancer patients, physicians say \(Pharmawire\)](#)